8/11/2022 7:32:15 AM
Theseus Pharma Q2 Net Loss $11.6 Mln Vs. Net Loss Of $6.8 Mln Prior Year
5/12/2022 7:23:14 AM
Theseus Pharma Q1 Net Loss $10.5 Mln Vs Loss Of $4.5 Mln Last Year
3/10/2022 4:38:52 PM
Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) FY22 Estimate To -1.11 From -1.42
3/10/2022 4:38:31 PM
Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q4 22 Estimate To -0.32 From -0.40
3/10/2022 4:38:17 PM
Wedbush Is Increasing Theseus Pharmaceuticals, Inc. (THRX) Q3 22 Estimate To -0.30 From -0.37
3/10/2022 4:37:57 PM
Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q2 22 Estimate To -0.25 From -0.34
3/10/2022 4:37:44 PM
Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q1 22 Estimate To -0.24 From -0.30
3/10/2022 4:37:02 PM
Wedbush Reiterates Theseus Pharmaceuticals, Inc. (THRX) At Outperform With $24 Price Target
3/10/2022 7:24:30 AM
Theseus Pharma Q4 Loss Widens To $8.7 Mln From $2.9 Mln Prior Year
2/2/2022 7:35:53 AM
Theseus Gets FDA Orphan Drug Designation For THE-630 For Treatment Of Advanced Gastrointestinal Stromal Tumors
11/15/2021 7:13:53 AM
Theseus Pharmaceuticals Q3 Net Loss Widens To $7.4 Mln From $1.4 Mln Last Year
11/1/2021 8:24:40 AM
Wedbush Starts THERAVANCE, INC. (THRX) At Outperform With $24 Price Target
10/6/2021 10:37:01 PM
Theseus Pharma Prices IPO Of 10.00 Mln Shares At $16.00/shr
8/6/2014 5:04:14 PM
THERAVANCE, INC. (THRX) Declares $ 0.25 Dividend for Q3 14, Record Date 8/28/2014
8/1/2012 8:09:49 AM
Robert W. Baird Is Raising THERAVANCE, INC. (THRX) FY12 Estimate To -0.30 From -0.33
5/1/2012 7:56:44 AM
Robert W. Baird Is Increasing THERAVANCE, INC. (THRX) FY 13 Estimate To -1.11 From -1.26